Janssen Settles Latest Risperdal Case Before Trial in Philadelphia

Risperdal causes gynecomastia, or enlarged breasts, in men.
Risperdal causes gynecomastia, or enlarged breasts, in men.

Janssen Pharmaceuticals Inc. settled the lawsuit of a New York boy who took the antipsychotic drug Risperdal and grew female breasts, just before the case was to go on trial in  Philadelphia County Court of Common Pleas, according to Law360.

The case is Zachary Sabol et al. v. Janssen Pharmaceuticals Inc. et al., case number 130402100, and the settlement amount was not disclosed. It would have been the seventh trial in Philadelphia’s mass tort program, where 2,300 cases are pending against the drug maker.

The plaintiff and his family filed suit against Janssen in 2013 charging that he developed gynecomastia, or the abnormal growth of female breast tissue, after being treated with Risperdal for nearly a decade.

The FDA approved Riserdal in 2006 for treating autism in adolescents. When Sabol began taking the drug, however, it was only approved for use in adults and indicated that gynecomastia was a rare side effect that occurred in fewer than one in 1,000 patients. Warning labels were later updated to show there was a 2.3 percent rate of gynecomastia in adolescents taking the drug.

The litigation has continued for three years in Philadelphia. Another 16,000 case are consolidated in California Superior Court in Los Angeles with the first trials set for July.  Three earlier trials have resulted in verdicts in favor of the injured plaintiff in the amount of $2.5 Million, $1.75 Million, and $500,000.  In all the trials, juries have found that J&J failed to adequately warn of the risks of gynecomastia.

Recent Headlines in Risperdal:

Infographic: The Disgraceful History of Risperdal

New Judge Knocks Out Plaintiff’s Expert, Abruptly Dismisses Risperdal Case

Plaintiffs Settle Risperdal Case with Johnson & Johnson in Philadelphia Court

Philly Judge Adds $6.66 Million Delay Interest to $70M Risperdal Verdict

Kentucky AG Settles Risperdal and OxyContin False Marketing Cases for $39.5 Million


Share this Post: